Half-year report · Q2
2385.TEDINET S100V7YR
Period2024-07-01 → 2024-12-31
Filed2025-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.8bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Operating income | −¥203m | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | −¥455m | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | −¥198m | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥566m | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥449m | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥212m | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥449m | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥222m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥662m | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥488m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥222m | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | −¥489m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥6.6bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥6.9bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥7.1bn | at 2023-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥557m | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥697m | at 2024-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥6.2bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.4bn | at 2023-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.6bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.8bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.6bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.8bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.9bn | at 2023-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥98m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥881m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥967m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥324m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥172,000 | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥261m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥260m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-8.5 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.32 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.65 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 91.3% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.7% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥14m |
| Reconciling Itemsreconciling | revenue external | 2024-07-01 → 2024-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥15m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | −¥159m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥152m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥152m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥19m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥751m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥751m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥25m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥4m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2024-07-01 → 2024-12-31 | −¥132m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥183m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥173m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥11m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥393m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥393m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥39m |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥2.7bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥2.7bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥15m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | −¥45m |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥10m |
| Reconciling Itemsreconciling | revenue external | 2023-07-01 → 2023-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥156m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥176m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥176m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥779m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥779m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥72m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥270m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥165m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥157m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥8m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2023-07-01 → 2023-12-31 | −¥701,000 |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥337m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥337m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥43m |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥2.9bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥2.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥11m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | −¥299m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 447
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 1311000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 42678000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | -72393000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | -269700000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | -701000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | -298805000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -156280000 | JPY |
| Operating income | Prior1YTDDuration | -455085000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 152167000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 392665000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 751093000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1213974000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 172607000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 2682508000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | 900000 | JPY |
| Revenues from external customers | CurrentYTDDuration | 2683408000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 4377000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 10871000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 15248000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -15248000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 152167000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 392665000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 751093000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1218352000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 183478000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 2697757000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -14348000 | JPY |
| Net sales | CurrentYTDDuration | 2683408000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 19371000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 39491000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 25139000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | -131746000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 3242000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -44501000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -158542000 | JPY |
| Operating income | CurrentYTDDuration | -203043000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-02-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第31期中（自 2024年７月１日 至 2024年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社総医研ホールディングス | |
| Company name in english cover page | FilingDateInstant | Soiken Holdings Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 角田 真佐夫 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府豊中市新千里東町一丁目４番２号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 06（6871）8888 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |